Evidence map›Paper›PMID 31720536›Full record

ArticleACS omega2019

Hydrophilic Fluorescent Nanoprodrug of Paclitaxel for Glioblastoma Chemotherapy.

Jonathan Daniel, Maeva Montaleytang, Sounderya Nagarajan, Sébastien Picard, Guillaume Clermont, Adina N Lazar, Noé Dumas, Florian Correard, Diane Braguer, Mireille Blanchard-Desce and 2 more

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Nanoparticles for Stem Cell Therapy Bioengineering in Glioma.Frontiers in bioengineering and biotechnology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Jonathan DanielUniv. Bordeaux, Institut des Sciences Moléculaires (CNRS UMR 5255), Bâtiment A12, 351 Cours de la Libération, 33405 Talence Cedex, France.
Maeva MontaleytangAix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Faculté de Pharmacie, 27 Boulevard Jean Moulin - CS 30064, 13385 Marseille Cedex 05, Marseille, France.
Sounderya NagarajanAix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Faculté de Pharmacie, 27 Boulevard Jean Moulin - CS 30064, 13385 Marseille Cedex 05, Marseille, France.
Sébastien PicardUniv. Bordeaux, Institut des Sciences Moléculaires (CNRS UMR 5255), Bâtiment A12, 351 Cours de la Libération, 33405 Talence Cedex, France.
Guillaume ClermontUniv. Bordeaux, Institut des Sciences Moléculaires (CNRS UMR 5255), Bâtiment A12, 351 Cours de la Libération, 33405 Talence Cedex, France.
Adina N LazarUniv. Bordeaux, Institut des Sciences Moléculaires (CNRS UMR 5255), Bâtiment A12, 351 Cours de la Libération, 33405 Talence Cedex, France.
Noé DumasAix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Faculté de Pharmacie, 27 Boulevard Jean Moulin - CS 30064, 13385 Marseille Cedex 05, Marseille, France.
Florian CorreardAix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Faculté de Pharmacie, 27 Boulevard Jean Moulin - CS 30064, 13385 Marseille Cedex 05, Marseille, France.
Diane BraguerAix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Faculté de Pharmacie, 27 Boulevard Jean Moulin - CS 30064, 13385 Marseille Cedex 05, Marseille, France.
Mireille Blanchard-DesceUniv. Bordeaux, Institut des Sciences Moléculaires (CNRS UMR 5255), Bâtiment A12, 351 Cours de la Libération, 33405 Talence Cedex, France.
Marie-Anne EstèveAix Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Faculté de Pharmacie, 27 Boulevard Jean Moulin - CS 30064, 13385 Marseille Cedex 05, Marseille, France.
Michel VaultierUniv. Bordeaux, Institut des Sciences Moléculaires (CNRS UMR 5255), Bâtiment A12, 351 Cours de la Libération, 33405 Talence Cedex, France.
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Highly water-soluble, nontoxic organic nanoparticles on which paclitaxel (PTX), a hydrophobic anticancer drug, has been covalently bound via an ester linkage (4.5% of total weight) have been prepared for the treatment of glioblastoma. These soft fluorescent organic nanoparticles (FONPs), obtained from citric acid and diethylenetriamine by microwave-assisted condensation, show suitable size (Ø = 17-30 nm), remarkable solubility in water, softness as well as strong blue fluorescence in an aqueous environment that are fully retained in cell culture medium. Moreover, these FONPs were demonstrated to show in vitro safety and preferential internalization in glioblastoma cells through caveolin/lipid raft-mediated endocytosis. The PTX-conjugated FONPs retain excellent solubility in water and remain stable in water (no leaching), while they showed anticancer activity against glioblastoma cells in two-dimensional and three-dimensional culture. PTX-specific effects on microtubules reveal that PTX is intracellularly released from the nanocarriers in its active form, in relation with an intracellular-promoted lysis of the ester linkage. As such, these hydrophilic prodrug formulations hold major promise as biocompatible nanotools for drug delivery.

Identifiers

PMID31720536
PMCPMC6844107
OpenAlexW2981555760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.